相关实验视频

Updated: Jun 9, 2025

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

加快动脉血栓的血栓溶解与NO-MBs UTMD疗法

Binbin Shi¹, Qiaohua Yang², Zenghui Liang³

¹Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

|October 30, 2024

概括

这项研究引入了含有氧化的脂质微泡 (NO-MBs) 与超声波向微泡破坏 (UTMD) 结合起来,以实现有效的动脉血栓溶解. 这种新的方法可以安全地减少炎症和氧化应激,显示出治疗血栓性疾病的巨大潜力.

科学领域:

生物医学工程生物医学工程
心血管研究研究心血管研究
纳米技术纳米技术

背景情况:

动脉血栓性疾病带来了重大的临床挑战.
氧化 (NO) 对血栓形成具有治疗效益,但面临着分娩和清除问题.
系统NO的使用可能会导致并发症和血红蛋白的快速降解.

研究的目的:

使用脂质微泡 (NO-MBs) 开发一种针对NO的向输送系统.
将NO-MBs与超声波向微气泡破坏 (UTMD) 结合起来,以增强血栓溶解.
评估NO-MBs UTMD战略的有效性,安全性和潜在机制.

主要方法:

设计和描述NO载脂质微气泡 (NO-MBs).
在试验室和体内使用NO-MBs和UTMD在超声指导下进行的血栓溶解实验.
评估炎症标志物 (例如SOD,MDA) 和氧化应激.
通过MTT测定,血液溶解测试,血清生物化学和组织学分析评估生物安全性.

主要成果:

通过UTMD,NO-MBs表现出良好的稳定性和有效的有针对性的NO输送.
NO-MBs和UTMD的组合显著加速了动脉血栓溶解.
治疗减少了血管组织中的炎症因素和氧化应激标志物.
广泛的安全评估表明,NO-MBs UTMD策略的生物安全性非常好.

结论:

NO-MBs UTMD 策略为治疗动脉血栓性疾病的向NO输送提供了一个有希望的方法.
这种方法有效地促进血栓溶解,同时减轻炎症和氧化应激.
证明的生物安全性支持其潜在的临床转化对血栓状况.

关键词:

动脉血栓性疾病是一种动脉血栓性疾病.脂质微气泡是一种微气泡.氧化氧化是什么?血栓溶解是一种血栓溶解.在UTMDD中使用.

更多相关视频

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Acute Coronary SyndromeI: Introduction

Acute Coronary SyndromeI: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.